Financial Position - Cash, cash equivalents, and short-term investments totaled approximately $340 million as of September 30, 2024, providing a runway into the second half of 2026[7] - Total current assets increased to $344,292 thousand as of September 30, 2024, up from $263,860 thousand at December 31, 2023, representing a growth of approximately 30.4%[11] - Cash and cash equivalents decreased to $79,540 thousand from $225,110 thousand, a decline of about 64.7%[11] - Short-term investments rose significantly to $260,576 thousand from $34,606 thousand, marking an increase of approximately 653.5%[11] - Total assets grew to $378,776 thousand, up from $297,674 thousand, reflecting an increase of about 27.2%[11] - Total current liabilities increased to $20,046 thousand from $17,928 thousand, an increase of approximately 11.8%[11] - Stockholders' equity rose to $331,560 thousand, up from $250,556 thousand, indicating an increase of about 32.3%[11] - Accumulated deficit widened to $(662,109) thousand from $(572,499) thousand, representing an increase of approximately 15.7%[11] - Common stock increased to $106 thousand from $78 thousand, reflecting a growth of approximately 35.9%[11] - Additional paid-in capital increased to $993,486 thousand from $823,029 thousand, a rise of about 20.7%[11] - Operating lease liabilities, non-current decreased to $27,170 thousand from $29,190 thousand, a decline of approximately 6.9%[11] Research and Development - Research and development (R&D) expenses for Q3 2024 were $30.1 million, an increase from $27.9 million in Q3 2023[7] - Topline data for the RWE comparability study for ANX005 in Guillain-Barré Syndrome (GBS) is expected by year-end 2024, supporting a BLA submission in the first half of 2025[6] - Ongoing Phase 3 ARCHER II trial for ANX007 in Geographic Atrophy (GA) is expected to enroll approximately 630 patients, with topline data anticipated in the second half of 2026[6] - Initial data from the proof-of-concept study for ANX1502 in Cold Agglutinin Disease (CAD) is expected in the first quarter of 2025[6] - ANX005 demonstrated statistically significant effects on the GBS-disability scale (GBS-DS), with early treatment effects leading to expedited recovery[4] Company Strategy and Leadership - The company strengthened its senior leadership team in commercial, medical affairs, and health economics to advance its late-stage neuroinflammatory-targeted portfolio[3] - The company aims to provide targeted therapies for over 8 million people worldwide suffering from neuroinflammatory diseases[8] Financial Performance - Net loss for Q3 2024 was $34.8 million, or $0.25 per share, compared to a net loss of $32.5 million, or $0.43 per share, in Q3 2023[7] - General and administrative (G&A) expenses for Q3 2024 were $9.3 million, compared to $6.9 million in Q3 2023[7]

Topline Real-World Evidence (RWE) Comparability and Outcomes Data for ANX005 in Guillain-Barré Syndrome (GBS) Expected by Year-End 2024; Biologics License Application (BLA) Submission Targeted for First Half 2025 Ongoing Enrollment in Phase 3 ARCHER II Trial for ANX007 in Geographic Atrophy (GA); Topline Data Expected Second Half 2026 Proof-of-Concept Study with First-in-Kind Oral C1s Inhibitor ANX1502 Transitioned to an Enhanced Tablet Formulation; Data in Cold Agglutinin Disease (CAD) Expected in First Q ...

BRISBANE, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company focused on upstream C1q to advance therapies for neuroinflammatory diseases of the body, brain and eye, today announced that Douglas Love, president and chief executive officer, will present at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024 at 10:30 a.m. GMT. A live webcast of the event can be accessed under the ‘Events & Presentations’ section on the Investors page at ww ...

Enhanced protection of vision with ANX007 treatment in healthier eyes Greater preservation of EZ in the central fovea by ANX007 in patients with less advanced GA Pivotal Phase 3 ARCHER II Data Expected Second Half 2026 BRISBANE, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company focused on upstream C1q to advance therapies for neuroinflammatory diseases of the body, brain and eye, today announced new findings from its Phase 2 ARCHER study for ANX007 in geogr ...

On October 1, 2024, Director William Carson purchased 3,200 shares of Annexon Inc (ANNX, Financial), as reported in a recent SEC Filing. The transaction occurred at a price of $5.97 per share, totaling $19,104. Following this transaction, the insider now owns 22,400 shares of the company. Annexon Inc focuses on the development of therapeutics for autoimmune and neurodegenerative disorders. The company's approach targets the classical complement pathway to prevent abnormal activation, which is a cause of the ...

Md Saiful Islam Khan/iStock via Getty Images Annexon, Inc. (NASDAQ:ANNX) is a clinical-stage biopharmaceutical developing innovative therapies targeting the classical complement pathway, particularly the C1q protein. When this pathway is overactivated, it can lead to an inflammation cascade that produces tissue damage. ANNX’s pipeline spans three areas: autoimmune diseases, neurodegenerative conditions, and ophthalmology. ANNX’s strategy aims to benefit a diverse range of complement-mediated illnesses. R ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39402 ANNEXON, INC. (Exact name of Registrant as specified in its Charter) Delaware 27-5414423 (State or other jurisdiction of in ...

Exhibit 99.1 Annexon Reports Second Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones Single, Well-Tolerated Infusion of ANX005 Significantly Accelerated Recovery of GBS Patients vs. Placebo in Pivotal Phase 3 Trial; Potential to be First Targeted Therapy for GBS; Topline Real-World Evidence (RWE) Comparability Data Now Expected by Year-End 2024 Dosing Initiated in ARCHER II Registrational Trial for ANX007; Only Program to Demonstrate Significant Vision Protection and Structural P ...

Patient Dosing Initiated in Phase 3 ARCHER II Trial of C1q Inhibitor ANX007; Topline Data Expected in Second Half 2026 Additional Data from Phase 2 ARCHER Trial Demonstrated Both Significant Vision Protection in Standard and Low Light Conditions, and Significant Structural Protection in Regions of the Eye Important for Visual Acuity BRISBANE, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing novel complement therapies for neuroinflammatory diseases ...

Company Overview - Annexon, Inc. is a biopharmaceutical company focused on developing novel therapies for neuroinflammatory diseases affecting the body, brain, and eye [2] - The company employs a unique scientific approach targeting upstream C1q to inhibit the classical complement inflammatory cascade [2] - Annexon is advancing a late-stage clinical platform with proof-of-concept data in conditions such as Guillain-Barré syndrome, Huntington's disease, and geographic atrophy [2] Recent Developments - On July 11, 2024, Annexon granted an equity award to a new non-executive employee under the 2022 Employment Inducement Award Plan [1] - The awarded option allows the purchase of 6,200 shares of Annexon common stock at an exercise price of $6.17, which reflects the closing price on July 15, 2024 [1] - The option has a ten-year term and vests over four years, with 25% vesting on the first anniversary and the remainder vesting monthly thereafter [1]